Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy

por Ni, Ying, Gao, Lixia, Lu, Yan, Ye, Shiguang, Zhou, Lili, Qian, Wenbin, Liang, Aibin, Li, Ping
Publicado 2022

SIRT1 inhibition impairs non-homologous end joining DNA damage repair by increasing Ku70 acetylation in chronic myeloid leukemia cells

por Zhang, Wenjun, Wu, Haixia, Yang, Meng, Ye, Shiguang, Li, Liang, Zhang, Hong, Hu, Jiong, Wang, Xuguang, Xu, Jun, Liang, Aibin
Publicado 2015

Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis

por Li, Ping, Zhou, Lili, Ye, Shiguang, Zhang, Wenjun, Wang, Junbang, Tang, Xiaochen, Liu, Jie, Xu, Yangyang, Qian, Wenbin, Liang, Aibin
Publicado 2021

Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma

por Liang, Zhiyu, Li, Ping, Kang, Liqing, Zhou, Lili, Xu, Yang, Ye, Shiguang, Du, Juan, Li, Bing, Wang, Yiwen, Yu, Lei, Qian, Wenbin, Liang, Aibin
Publicado 2022